---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-037180"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T14:30:09.859339+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Esperion Q3 total revenue $34M (+79% YoY); FDA PDUFA date March 31, 2024

## Summary
- Q3 total revenue $34.0M (+79% YoY); U.S. product revenue $20.3M (+45% YoY).
- Net loss $41.3M ($0.37 per share) vs $55.1M ($0.81) in prior year.
- FDA accepted sNDA for expanded CV risk reduction label; PDUFA date March 31, 2024.
- Cash $114.8M at Sep 30 vs $166.9M at Dec 31; FY 2023 OpEx guidance $225-245M.
- Presented CLEAR Outcomes analyses at ESC showing 20% reduction in total MACE.

## SEC filing metadata
- accession: 0001628280-23-037180
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828023037180/0001628280-23-037180-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828023037180/espr-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-037180
- JSON: https://secwatch.observer/filing/0001628280-23-037180.json
- Plain text: https://secwatch.observer/filing/0001628280-23-037180.txt

## Key facts
- Earnings Releases
  Esperion Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: revenue $34.0 million, net income $41.3 million, EPS $0.37.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $34.0 million
  - Net income: $41.3 million
  - EPS: $0.37
  - Result: reported results
  source text: --- EX-99.1 (EX-99.1) --- Esperion Reports Third Quarter 2023 Financial Results – Q3 U.S. Net Product Revenue Grew 45% Y/Y to $20.3 Million; Q3 Total Revenue Grew 79% Y/Y to $34.0 Million – – Q3 Retail Prescription Equivalents Grew 33% Y/Y and 8% Q/Q, Demonstrating Sustained Momentum into 2H 2023 – – Received FDA Acceptance of Application for Expanded CV Risk
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000162828023037180/0001628280-23-037180-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.